Infrequent bax gene mutations in B-cell lymphomas

Journal of Pathology

Volumn 186, Issue 4, 1998, Pages 378-382

  Peng, Huaizheng ^a   Aiello, Antonella ^b   Packham, Graham ^c   Isaacson, Peter G ^a   Pan, Langxing ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Apoptosis; B cell lymphoma; Bax gene mutation; PCR SSCP

Indexed keywords

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; HUMAN; HUMAN TISSUE; OPEN READING FRAME; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

BCL-2-ASSOCIATED X PROTEIN; DNA, NEOPLASM; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0032445618     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5     Document Type: Article

References (36)

1. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
2. Kernohan NM, Cox LS. Regulation of apoptosis by Bcl-2 and its related proteins: immunochemical challenges and therapeutic implications (Editorial). J Pathol 1996; 179: 1-3.
3. Magrath I. Molecular basis of lymphomagenesis. Cancer Res 1992; 52: 5529s-5540s.
4. Korsmeyer SJ. Regulators of cell death. Trends Genet 1995; 11: 101-105.
5. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 1995; 82-83: 155-158.
6. Ottilie S, Diaz JL, Chang J, et al. Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation. J Biol Chem 1992; 272: 16955-16961.
7. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
8. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997; 3: 614-620.
9. Hunter JJ, Bond BL, Parslow TG. Functional dissection of the human Bcl2 protein: sequence requirements for inhibition of apoptosis. Mol Cell Biol 1996; 16: 877-883.
10. Yin XM, Oltvai ZN, Korsmeyer SJ. Heterodimerization with Bax is required for Bcl-2 to repress cell death. Curr Top Microbiol Immunol 1995; 194: 331-338.
11. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
12. Chou D, Miyashita T, Mohrenweiser HW, et al. The Bax gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996; 88: 136-140.
13. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
14. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
15. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 1994; 9: 1791-1798.
16. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
17. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96-99.
18. Meijerink JP, Smetsers TF, Sloetjes AW, Linders EH, Mensink EJ. Bax mutations in cell lines derived from hematological malignancies. Leukemia 1995; 9: 1828-1832.
19. Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1997; 57: 4420-4426.
20. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
21. Brimmell M, Mendiola R, Mangion J, Packham G. Bax frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1997; 15.
22. Meijerink JP, Mensink EJ, Raemaekers JM, Sloetjes AW, Korsmeyer SJ, De Witte T. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1997; 10: 1843-1844 (Abstract).
23. Diss TC, Pan LX, Peng HZ, Wotherspoon AC, Isaacson PG. Sources of DNA for detecting B cell monoclonality using PCR. J Clin Pathol 1994; 47: 493-496.
24. Diss TC, Peng HZ, Wotherspoon AC, Isaacson PG, Pan L. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol 1993; 169: 291-295.
25. Pan LX, Diss TC, Peng HZ, Isaacson PG. Clonality analysis of defined B-cell populations in archival tissue sections using microdissection and the polymerase chain reaction. Histopathology 1994; 24: 323-327.
26. Peng H, Chen G, Du M, Singh N, Isaacson PG, Pan L. Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 1996; 148: 643-648.
27. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995; 86: 4587-4593.
28. Manetto V, Lorenzini R, Cordon Cardo C, et al. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Arch 1997; 430: 125-130.
29. Krajewski S, Krajewska M, Ehrmann J, et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-814.
30. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-1576.
31. Ohta K, Iwai K, Kasahara Y, et al. Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol 1995; 7: 1817-1825.
32. Krajewska M, Fenoglio Preiser CM, Krajewski S, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996; 149: 1449-1457.
33. Branet F, Brousset P, Krajewski S, et al. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab 1996; 81: 2726-2730.
34. Peng HZ, Du MQ, Ji JX, Isaacson PG, Pan LX. High-resolution SSCP analysis using acrylamide-agarose composite gel and a background free silver staining method. Biotechniques 1995; 19: 410-413.
35. Ngan BY, Berinstein N. Oncogene involvement in lymphoid malignancy. Tumour Biol 1990; 11 (Suppl 1): 78-93.
36. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562.